PMN vs PRTA vs ARVN vs ACAD vs SAVA vs JPM

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate ProMIS Neurosciences, Inc. (PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 2x versus JPMorgan Chase & Co. at 16. 0x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: JPM returned +465. 8% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 104% more volatile than JPM relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 176. 7x for Prothena Corporation plc — 162. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. PMN, PRTA, ARVN, ACAD, SAVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PMN (Healthcare) and PRTA (Healthcare) and ARVN (Healthcare) and ACAD (Healthcare) and SAVA (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PMN is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; ARVN is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; SAVA is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while PMN, PRTA, ARVN, ACAD, SAVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.